Anzeige
Mehr »
Freitag, 06.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PS0P | ISIN: US92764N1028 | Ticker-Symbol:
NASDAQ
06.06.25 | 16:59
5,405 US-Dollar
+4,44 % +0,230
1-Jahres-Chart
VIR BIOTECHNOLOGY INC Chart 1 Jahr
5-Tage-Chart
VIR BIOTECHNOLOGY INC 5-Tage-Chart

Aktuelle News zur VIR BIOTECHNOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
29.05.Vir Biotechnology, Inc. - 8-K, Current Report4
22.05.Vir Biotechnology Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)6
20.05.Vir Biotechnology stock target cut to $15 by H.C. Wainwright2
VIR BIOTECHNOLOGY Aktie jetzt für 0€ handeln
09.05.Vir's 'functional cure' candidate for hepatitis B misses mark in phase 27
09.05.Vir announces 24-week post-end of treatment data for Hep B therapy2
09.05.Vir Biotechnology, Inc.: Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study336HBsAg loss 24 weeks post-end of treatment achieved in 17% and 21% of participants with low baseline HBsAg receiving tobevibart elebsiran without or with PEG-IFNa, respectively As previously...
► Artikel lesen
08.05.Vir Biotechnology announces initiation of ECLIPSE Phase III program for hepatitis delta virus11
07.05.Vir Biotechnology, Inc. - 8-K, Current Report4
06.05.Vir Biotechnology Q1 2025 Earnings Preview5
06.05.Earnings Outlook For Vir Biotechnology4
24.04.Vir Biotechnology, Inc.: Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025322Phase 2 SOLSTICE subgroup analysis data in chronic hepatitis delta selected for poster presentation, and to be highlighted during EASL poster tour 24 Week post-treatment follow-up data...
► Artikel lesen
17.04.5 Analysts Have This To Say About Vir Biotechnology4
13.03.Morgan Stanley maintains $20 target on Vir Biotechnology stock7
28.02.7 Analysts Have This To Say About Vir Biotechnology4
27.02.Vir, awaiting 'functional cure' data for hep B combo, won't take treatment forward alone4
27.02.Vir Biotechnology, Inc. - S-8, Securities to be offered to employees in employee benefit plans-
26.02.Vir Biotechnology GAAP EPS of -$0.76 beats by $0.10, revenue of $12.37M beats by $4.23M4
26.02.Vir Biotechnology, Inc. - 8-K, Current Report1
30.01.Vir Biotechnology, Inc. - 8-K, Current Report1
24.01.Why Vir Biotechnology, Inc. (VIR) Is Skyrocketing Now6
Weiter >>
37 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,2